生物活性 | |||
---|---|---|---|
靶点 |
|
||
描述 | NMS-P118 is a potent, orally available, and highly selective PARP-1 inhibitor for cancer therapy with an IC50 of 0.04 μM in HeLa cell. |
细胞研究 | |||||
---|---|---|---|---|---|
细胞系 | 浓度 | 检测类型 | 检测时间 | 活动说明 | 数据源 |
HeLa cells | Function assay | 30 mins | Inhibition of PARP1 in human HeLa cells assessed as reduction of H2O2-induced PAR formation preincubated for 30 mins followed by H2O2 addition measured after 15 mins by immunocytochemical analysis, IC50=0.04 μM | 26222319 | |
MDA-MB-436 cells | Cytotoxicity assay | 10 to 14 days | Cytotoxicity against BRCA1-deficient human MDA-MB-436 cells assessed as inhibition of colony formation after 10 to 14 days by crystal violet staining, IC50=0.14 μM | 26222319 |
实验方案 | |||
---|---|---|---|
1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
2.53mL 0.51mL 0.25mL |
12.64mL 2.53mL 1.26mL |
25.29mL 5.06mL 2.53mL |
参考文献 |
---|